Brainsway Ltd., which is developing a noninvasive medical device that treats brain-related disorders, announced terms for its IPO on Thursday. The Jerusalem, Israel-based company plans to raise $10 million by offering one million shares at a price range of $9 to $11. At the mid-point of the proposed range, Brainsway Ltd. will command a market value of $134 million. Brainsway Ltd., which was founded in 2003 and booked $143 thousand in sales for the 12 months ended March 31, 2011, plans to list on the NASDAQ under the symbol BRIN. Roth Capital is the lead underwriters on the deal.